Glioblastoma-targeted, local and sustained drug delivery system based on an unconventional lipid nanocapsule hydrogel

Biomater Adv. 2023 Oct:153:213549. doi: 10.1016/j.bioadv.2023.213549. Epub 2023 Jul 4.

Abstract

The objective of this work was to develop an implantable therapeutic hydrogel that will ensure continuity in treatment between surgery and radiochemotherapy for patients with glioblastoma (GBM). A hydrogel of self-associated gemcitabine-loaded lipid nanocapsules (LNC) has shown therapeutic efficacy in vivo in murine GBM resection models. To improve the targeting of GBM cells, the NFL-TBS.40-63 peptide (NFL), was associated with LNC. The LNC-based hydrogels were formulated with the NFL. The peptide was totally and instantaneously adsorbed at the LNC surface, without modifying the hydrogel mechanical properties, and remained adsorbed to the LNC surface after the hydrogel dissolution. In vitro studies on GBM cell lines showed a faster internalization of the LNC and enhanced cytotoxicity, in the presence of NFL. Finally, in vivo studies in the murine GBM resection model proved that the gemcitabine-loaded LNC with adsorbed NFL could target the non-resected GBM cells and significantly delay or even inhibit the apparition of recurrences.

Keywords: Glioblastoma; Hydrogel; Lipid nanocapsules; Sustained release; Targeting.

MeSH terms

  • Animals
  • Brain Neoplasms* / drug therapy
  • Brain Neoplasms* / metabolism
  • Drug Delivery Systems
  • Gemcitabine
  • Glioblastoma* / drug therapy
  • Glioblastoma* / metabolism
  • Humans
  • Hydrogels / therapeutic use
  • Lipids / chemistry
  • Lipids / therapeutic use
  • Mice
  • Nanocapsules* / chemistry
  • Nanocapsules* / therapeutic use

Substances

  • Nanocapsules
  • Hydrogels
  • Gemcitabine
  • Lipids